LEADER 01533nam  2200397Ia 450 
001 9910698833903321
005 20090526104004.0
035   $a(CKB)5470000002397528
035   $a(OCoLC)351399149
035   $a(EXLCZ)995470000002397528
100   $a20090526d2003      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $enotifying FDA of fatalities related to blood collection or transfusion
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2003]
215   $a5 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 26, 2009).
300   $a"Final guidance".
300   $a"September 2003".
517   $aGuidance for industry 
606   $aBlood$xTransfusion$xGovernment policy$zUnited States
606   $aBlood$xCollection and preservation$xGovernment policy$zUnited States
606   $aDeath notification$xGovernment policy$zUnited States
615  0$aBlood$xTransfusion$xGovernment policy
615  0$aBlood$xCollection and preservation$xGovernment policy
615  0$aDeath notification$xGovernment policy
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698833903321
996   $aGuidance for industry$93434577
997   $aUNINA